The Adult Blood and Bone Marrow Transplant Program

The Adult Blood and Marrow Transplant (BMT) Program is led by Dr. Philip L McCarthy, MD along with Drs. Maureen Ross, MD, and Hong Liu, MD and George Chen, MD who provide patient care along with a dedicated team of nurse practitioners, transplant coordinators, epide miologists, psychologists, case managers, pharmacists, social workers, physical therapists, and in-patient and out-patient nurses. The mission of BMT program is to provide outstanding clinical care for BMT patients and to conduct research that will improve BMT patient outcomes. Disorders such as Acute and Chronic Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Aplastic Anemia and selected solid tumors are treated with BMT.

The BMT Program research focuses on the following major areas:

  • Drs. Theresa Hahn  in collaboration with Drs. Lara Sucheston and Christine Ambrosone from the Department of Cancer Prevention and Control are conducting research on the role of genetic polymorphisms and BMT outcomes. These include a) chemotherapy metabolism gene polymorphisms and BMT toxicities, b) cytokine gene polymorphisms and Graft-versus-Host Disease (GvHD) and c) bone metabolism gene polymorphisms and accelerated osteoporosis and avascular necrosis which are frequent complications of BMT survivors.  Further Drs. Hahn and Sucheston were recently awarded a NIH grant conduct a Genome Wide Association study on 2500 donor and recipient unrelated donor pairs undergoing allogeneic transplant.  Dr. McCarthy is a co-investigator on this grant. This study will be conducted in collaboration with the Center for International Blood and Marrow Transplant Research with research input from investigators at University of Southern California and University of Chicago.
  • The BMT program is collaborating with Dr. Elizabeth Repasky from the Department of Immunology to develop a mouse BMT model of GvHD and Graft-versus Leukemia (GvL). This model will facilitate the understanding of GvHD .
  • The BMT program is collaborating with Dr. Andrei Gudkov and Cleveland BioLabs to investigate the utility of Toll-Like Receptor (TLR) agonists in pre-clinical (mouse) hematopoietic stem cell mobilization and immune modulation. This would be translated into clinical BMT applications.
  • Dr. Chen is examining novel approaches to the evaluation and treatment of chronic GvHD and will be opening a new study in collaboration with Dr. David Miklos from Stanford University Medical Center.  Further, he is collaborating with Dr. Chulhong Kim at UB to develop a non-invasive approach to quantifying skin chronic GvHD.
  • Dr. Liu is conducting a pilot study of reduced intensity transplant to determine if a novel conditioning regimen will lead to better outcomes in allogeneic transplant.  This study is being conducted in collaboration with the RPCI Radiation Oncology Department.
  • Dr. Ross will be conducting a novel approach to the control of acute GvHD by incorporating rituximab, an anti-B cell antibody into the conditioning regimen of patients undergoing allogeneic BMT.  She will analyze these results to determine if rituximab will lead to a lower level of acute and chronic GvHD and lead to better patient outcomes.
  • All transplant physicians participate in cooperative group trials through the BMT Clinical Trials Network and the Cancer and Leukemia Group B (CALGB).